BridgeBio gains on phase 3 dwarfism data
Shares in BridgeBio rose after it revealed data from a trial of infigratinib in achondroplasia, raising the prospect of the first oral treatment.
Newsletters and Deep Dive digital magazine
Shares in BridgeBio rose after it revealed data from a trial of infigratinib in achondroplasia, raising the prospect of the first oral treatment.
Cary Claiborne, CEO of Adial Pharmaceuticals, discusses his company’s bet on a precision treatment for AUD.
The UK government has asked the NHS to start putting together the platforms to allow anonymised primary care patient data to be used by researchers.
The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs.
The FDA said it needs more information before it can approve Regenxbio's gene therapy for Hunter syndrome, in a devastating decision for patients.
Editor's Picks
Newsletters and Deep Dive
digital magazine